Science and Enterprise

Tag: equity

  • Drug Developer BioCryst to Acquire Presidio Pharmaceuticals

    BioCryst Pharmaceuticals Inc. in Durham, North Carolina and Presidio Pharmaceuticals Inc. in San Francisco agreed to a merger of the biopharmaceutical companies. The deal in which BioCryst acquires Presidio is an all-stock transaction valued at $101 million. The merger will combine two clinical stage drug development operations that the companies say will focus on infectious…

  • Immunotherapy Developer Gains $4.9M in Series B Funds

    Gliknik Inc., a biopharmaceutical company in Baltimore, raised $4.9 million in series B funds, the second series of financing after initial start-up. Baxter Ventures led the funding round, joined by the company’s existing investors. Gliknik is a developer of therapies for patients with cancer and immune disorders that use the power of the immune system…

  • Drug Discovery Company Lands Venture Funds, Licensing Deal

    Vascular Pharmaceuticals Inc., a drug discovery company in Chapel Hill, North Carolina, secured $16 million in series A funds, the first round of financing after start-up. The company, a developer of drugs to treat complications of diabetes, also signed a licensing agreement for its lead compound with Janssen Biotech, a division of Johnson & Johnson.…

  • Biopharma Start-Up Secures $27 Million in Venture Funding

    Aerpio Therapeutics, a biopharmaceutical company in Cincinnati, closed a $27 million series A financing deal, the first round of funding after initial start-up. The round was led by Novartis BioVentures with Venture Investors LLC, Triathlon Medical Ventures, Kearny Venture Partners, Athenian Venture Partners, and AgeChem Venture Fund. The company began in January 2012 as a…

  • Janssen Licenses Biotech’s Antibody for Multiple Myeloma

    Janssen Pharmaceutical Companies, a division of Johnson & Johnson in Horsham, Pennsylvania, agreed to license a cancer drug targeting multiple myeloma made by biotechnology company Genmab A/S in Copenhagen, Denmark. The agreement has a total potential value of $1.1 billion from upfront, milestone, and royalty payments, as well as an equity investment in Genmab. The…

  • Health Care Technology Accelerator Boosts Seed Funding

    Rock Health, an organization that provides seed funding, training, and mentoring for start-up companies in health care technology, says its next class of companies will each receive a $100,000 investment. The funds for these start-ups are being provided by the Mayo clinic and three venture capital firms: Aberdare Ventures, Kleiner Perkins Caufield and Byers, and…

  • Medical Device Company Gets $20M in Venture Financing

    Ornim Inc., a developer of blood oxygen and blood flow monitors in Lod, Israel, secured $20 million in series B venture funding, the second financing cycle after initial start-up. The round was led by life sciences investment firm OrbiMed, with participants including the GE healthymagination Fund and Agate Medical Investments LP. Ornim develops monitors focusing…

  • Medical Monitor Device Start-Up Raises $7M in Venture Funds

    Retia Medical, a medical device company in East Lansing, Michigan, raised $7 million in series A funds, the first round of financing after initial start-up. The Pritzker/Vlock family office, a private equity company investing in biotech, industrial and medical equipment, and technology businesses led the round. Retia Medical develops monitors for high-risk patients, starting with…

  • Biopharm Raises $80 Million in Series C Venture Funds

    Relypsa Inc., a clinical stage biopharmaceutical company in Santa Clara, California raised $80 million in series C venture funds, the third round of financing after initial start-up. New investor Sibling Capital LLC joins current backers OrbiMed Advisors, 5AM Ventures, New Leaf Venture Partners, Sprout Group, Delphi Ventures, and Mediphase Venture Partners in this funding round.…

  • Biotech Chemical Company Raises $41.5M in Venture Funds

    Genomatica, a developer of chemicals from renewable feedstocks in San Diego, raised $41.5 million in series D financing, the fourth cycle of venture funding after start-up. The round includes the Italian chemical company and new corporate partner Versalis, with existing investors Alloy Ventures, Draper Fisher Jurvetson, Mohr Davidow Ventures, TPG Biotech, VantagePoint Capital Partners, and…